Abstract
Sudden cardiac arrest is a leading cause of death worldwide with survival rates still remaining suboptimal. Unfortunately, most cardiac arrest patients, who achieve return of spontaneous circulation (ROSC), develop a multi-faceted post-cardiac arrest syndrome, including post-cardiac arrest brain injury, myocardial dysfunction, and systemic ischemia/reperfusion response.
Erythropoietin (EPO), the principal hematopoietic hormone regulating erythropoiesis, exhibits diverse cellular effects in nonhematopoietic tissues. Due to its anti-apoptotic, anti-inflammatory, and anti-oxidant properties, as well as its angiogenic action, EPO plays a role in neuroprotection and cardioprotection. In this regard, EPO represents a promising agent in the cardiac arrest setting, based on a therapeutic strategy that focuses on the post-resuscitation phase.
This review aims to provide a comprehensive account of EPOs role in the treatment of each individual component of post-cardiac arrest syndrome.
Keywords: Erythropoietin, Cardiac arrest, Post-cardiac arrest syndrome, Neuroprotection, Cardioprotection, Anti-oxidant, hematopoietic, heterotrimer, dysfunction, reperfusion, homeostasis, cardiopulmonary, leukocytes, apoptotic, P-selectin, astrocytes, hypoxic, necrosis
Current Pharmaceutical Design
Title: The Potential Role of Erythropoietin as a Pleiotropic Agent in Post-cardiac Arrest Syndrome
Volume: 17 Issue: 15
Author(s): Theodoros Xanthos, Panagiotis V.S. Vasileiou, Sotirios Kakavas, Aggeliki Syggelou and Nicoletta Iacovidou
Affiliation:
Keywords: Erythropoietin, Cardiac arrest, Post-cardiac arrest syndrome, Neuroprotection, Cardioprotection, Anti-oxidant, hematopoietic, heterotrimer, dysfunction, reperfusion, homeostasis, cardiopulmonary, leukocytes, apoptotic, P-selectin, astrocytes, hypoxic, necrosis
Abstract: Sudden cardiac arrest is a leading cause of death worldwide with survival rates still remaining suboptimal. Unfortunately, most cardiac arrest patients, who achieve return of spontaneous circulation (ROSC), develop a multi-faceted post-cardiac arrest syndrome, including post-cardiac arrest brain injury, myocardial dysfunction, and systemic ischemia/reperfusion response.
Erythropoietin (EPO), the principal hematopoietic hormone regulating erythropoiesis, exhibits diverse cellular effects in nonhematopoietic tissues. Due to its anti-apoptotic, anti-inflammatory, and anti-oxidant properties, as well as its angiogenic action, EPO plays a role in neuroprotection and cardioprotection. In this regard, EPO represents a promising agent in the cardiac arrest setting, based on a therapeutic strategy that focuses on the post-resuscitation phase.
This review aims to provide a comprehensive account of EPOs role in the treatment of each individual component of post-cardiac arrest syndrome.
Export Options
About this article
Cite this article as:
Xanthos Theodoros, V.S. Vasileiou Panagiotis, Kakavas Sotirios, Syggelou Aggeliki and Iacovidou Nicoletta, The Potential Role of Erythropoietin as a Pleiotropic Agent in Post-cardiac Arrest Syndrome, Current Pharmaceutical Design 2011; 17 (15) . https://dx.doi.org/10.2174/138161211796197115
DOI https://dx.doi.org/10.2174/138161211796197115 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis, Cyclooxygenase-2 Inhibition, Anti-inflammatory Evaluation and Docking Study of Substituted-N-(3,4,5-trimethoxyphenyl)-benzo[d]oxazole Derivatives
Medicinal Chemistry The Role of Inflammation in Neurological Disorders
Current Pharmaceutical Design Xuesaitong May Protect Against Ischemic Stroke by Modulating Microglial Phenotypes and Inhibiting Neuronal Cell Apoptosis via the STAT3 Signaling Pathway
CNS & Neurological Disorders - Drug Targets Novel Self-micro Emulsifying Drug Delivery System for Safe Intramuscular Delivery with Improved Pharmacodynamics and Pharmacokinetics
Current Drug Delivery Drug Delivery Systems for the Treatment of Diabetes Mellitus: State of the Art
Current Pharmaceutical Design Levosimendan Reduces Prostaglandin F2a-dependent Vasoconstriction in Physiological Vessels and After Experimentally Induced Subarachnoid Hemorrhage
Current Neurovascular Research Antibody Mediated Rejection in Pig-To-Nonhuman Primate Xenotransplantation Models
Current Drug Targets - Cardiovascular & Hematological Disorders NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy
Current Medicinal Chemistry Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology The Role of Peripheral Benzodiazepine Receptors (PBRs) in CNS Pathophysiology
Current Medicinal Chemistry Peripheral Chemo-Cytokine Profiles in Alzheimers and Parkinsons Diseases
Mini-Reviews in Medicinal Chemistry Pharmacokinetics-Pharmacology Disconnection of Herbal Medicines and its Potential Solutions with Cellular Pharmacokinetic-Pharmacodynamic Strategy
Current Drug Metabolism Could Hippocampal Neurogenesis be a Future Drug Target for Treating Temporal Lobe Epilepsy?
CNS & Neurological Disorders - Drug Targets 2-(ω-Carboxyethyl)pyrrole Antibody as a New Inhibitor of Tumor Angiogenesis and Growth
Anti-Cancer Agents in Medicinal Chemistry Anticonvulsant and Antinociceptive Actions of Novel Adenosine Kinase Inhibitors
Current Topics in Medicinal Chemistry Exploiting the Diversity of the Heat-Shock Protein Family for Primary and Secondary Tauopathy Therapeutics
Current Neuropharmacology PET Radioligands for In Vivo Visualization of Neuroinflammation
Current Pharmaceutical Design The Pentacyclic Triterpenoids in Herbal Medicines and Their Pharmacological Activities in Diabetes and Diabetic Complications
Current Medicinal Chemistry Coumarin Compounds in Medicinal Chemistry: Some Important Examples from the Last Years
Current Topics in Medicinal Chemistry NMDA/NR2B Selective Antagonists in the Treatment of Ischemic Brain Injury
Current Drug Targets - CNS & Neurological Disorders